RNA-transfected dendritic cell vaccine (RNA-DC vaccine)

RNA-transfected dendritic cell vaccines are a form of personalized cancer immunotherapy designed to elicit a broad and specific anti-tumor immune response. This approach involves harvesting a patient's own dendritic cells and transfecting them with messenger RNA (mRNA) that encodes specific tumor-associated antigens or the entire tumor transcriptome. Once transfected, these dendritic cells function as superior antigen-presenting cells, displaying antigenic peptides via both MHC class I and MHC class II pathways to stimulate both CD8+ cytotoxic T-lymphocytes and CD4+ helper T-lymphocytes (Heiser et al., 2002, J Clin Invest [PMID: 11861451]). This dual activation is critical for overcoming tumor-induced immune tolerance and establishing long-term immunological memory. The use of RNA allows for the presentation of multiple epitopes without the need for prior knowledge of the patient's HLA type, making it a versatile platform for various malignancies such as melanoma and renal cell carcinoma (Su et al., 2003, Cancer Res [PMID: 12750283]). While generally well-tolerated, the clinical efficacy of these vaccines is often enhanced when used in combination with other immunomodulators like checkpoint inhibitors or cytokines. This modality represents a sophisticated intersection of cell therapy and molecular vaccinology aimed at harnessing the patient's own immune system to target and destroy malignant cells.

Other names

Autologous RNA-transfected dendritic cellsmRNA-pulsed dendritic cell vaccineDC-based immunotherapyAntigen-presenting cell therapyT-lymphocyte activation via RNA-pulsed DC

Autologous dendritic cells are transfected ex vivo with mRNA encoding tumor-associated antigens; these cells then translate the mRNA and process the resulting proteins into peptides for presentation on both MHC class I and MHC class II molecules to activate a dual CD8+ and CD4+ T-cell response (Gilboa, 2007, Nat Rev Cancer [PMID: 17522663]).